Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 5:06 PM ET


Company Overview of Receptos, Inc.

Company Overview

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...

3033 Science Park Road

Suite 300

San Diego, CA 92121

United States

Founded in 2008

68 Employees





Key Executives for Receptos, Inc.

Scientific Founder and Member of Scientific Advisory Board
Chief Financial Officer
Age: 58
Senior Vice President, General Counsel and Secretary
Age: 48
Senior Vice President of Corporate Development
Age: 50
Compensation as of Fiscal Year 2015.

Receptos, Inc. Key Developments

Receptos, Inc. Announces Executive Changes

Receptos, Inc. entered into an agreement and plan of merger with Celgene Corporation. In accordance with the terms of the Merger Agreement, as of the effective time, each of William H. Rastetter, Ph. D., Kristina Burow, Mary Lynne Hedley, Ph. D., Richard A. Heyman, Ph. D., Erle T. Mast, Mary Szela, S. Edward Torres and Faheem Hasnain ceased serving as directors of the company, and the directors of Purchaser at the Effective Time became the directors of the Surviving Corporation. Additionally, in accordance with the terms of the Merger Agreement, as of the Effective Time, each of Faheem Hasnain, Graham Cooper, Sheila K. Gujrathi, M.D., Marcus F. Boehm, Ph.D. and Robert Peach, Ph.D. ceased serving as officers of the Company.

Receptos, Inc.(NasdaqGS:RCPT) dropped from NASDAQ Composite Index

Receptos, Inc. will be removed from Nasdaq Composite Index.

Receptos, Inc.(NasdaqGS:RCPT) dropped from NASDAQ Biotechnology Index

Receptos, Inc. will be removed from NASDAQ Biotech Index.

Similar Private Companies By Industry

Company Name Region
Biopolymer Innovations, LLC United States
Satoris, Inc. United States
UberSeq, Inc. United States
Affinivax Inc. United States
Pure Transplant Solutions, L.L.C United States

Recent Private Companies Transactions

July 14, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Receptos, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at